stockrowCRISPR Therapeutics AG
CRSP Healthcare Biotechnology
CRISPR Therapeutics AG’s revenue for fiscal 2025 (year ended December 2025) was $3.5 million, down 90.6% from fiscal 2024.
- Revenue
- +1,325.1%
- EPS
- +1.55%
- Free cash flow
- −6.36%
Quarter to September 2026, against a year earlier
Follow CRSP
Alert me
CRISPR Therapeutics AG (CRSP) Book value per share
CRISPR Therapeutics AG's book value per share at the end of fiscal 2025 was 21.4×, down 6.69% from 22.9× in fiscal 2024. At the end of the quarter to 30 September 2026 it was 17.0×. Over the past ten years it has ranged from −5.8× (fiscal 2015) to 31.6× (fiscal 2021); the current reading is higher than 55% of that period. CRISPR Therapeutics AG ranks 42nd of 611 Biotechnology companies by book value per share.
Book value per share, annual
Embed this chart
Annual newest first
| Period | Book value per share | Change |
|---|---|---|
| FY2025 | 21.4× | (6.69%) |
| FY2024 | 22.9× | (3.63%) |
| FY2023 | 23.8× | (1.48%) |
| FY2022 | 24.1× | (23.65%) |
| FY2021 | 31.6× | 25.20% |
| FY2020 | 25.2× | 46.11% |
| FY2019 | 17.3× | 111.22% |
| FY2018 | 8.2× | 74.38% |
| FY2017 | 4.7× | (75.32%) |
| FY2016 | 19.0× | — |
Quarterly newest first
| Period | Book value per share | Change |
|---|---|---|
| Sep 2026 | 17.0× | (5.86%) |
| Jun 2026 | 18.1× | (4.21%) |
| Mar 2026 | 18.9× | (11.60%) |
| Dec 2025 | 21.4× | 1.84% |
| 40 more quarters | Free account |
Against its own ten years
Book value per share against peers
| Company | Book value per share |
|---|---|
| DNTH Dianthus Therapeutics, Inc. compare | 21.6× |
| MANE Veradermics Incorporated compare | 20.1× |
| CRSP CRISPR Therapeutics AG | 17.0× |
| EWTX Edgewise Therapeutics, Inc. compare | 15.0× |
| DFTX Definium Therapeutics, Inc. compare | 8.3× |
| LEGN Legend Biotech Corporation Sponsored ADR compare | 6.6× |
| COGT Cogent Biosciences, Inc. compare | 3.1× |
| ERAS Erasca, Inc. compare | 1.2× |
| TVTX Travere Therapeutics, Inc. compare | 0.2× |
What Book value per share is
BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.
(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))
More on CRSP
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement